Centre charts course for Hyd as global medical hub

Metro India News | Hyderabad 

The Central Government has unveiled a comprehensive policy framework designed to catalyse investment, attract global talent, and establish the city as a preferred destination for medical and pharma sector growth. The initiative, underscored by targeted fiscal incentives, regulatory streamlining, and infrastructure development.  

Hyderabad has emerged as India's second-largest pharmaceutical manufacturing hub and a growing centre for medical device innovation. The city is home to over 1,500 pharmaceutical units, accounting for approximately 13 per cent of India's total pharmaceutical exports. More than 15,000 medical device manufacturers operate in the region, with an annual production capacity valued at approximately Rs 45,000 crore.

Key pillars of the Central Government's policy initiative include enhanced research and development incentives, capital investment support for infrastructure modernization, expedited regulatory approvals and dedicated skilling programmes. The framework provides for concessional interest rates on loans for pharmaceutical and medical device manufacturing units, tax credits for R&D expenditure, and fast-tracked approvals for facility expansions and new product certifications.

Government officials articulated four strategic objectives driving the policy initiative. First, to increase the share of pharmaceutical and medical device manufacturing in India's global exports by establishing Hyderabad as a preferred hub for quality manufacturing and innovation. Second, to attract leading multinational pharmaceutical firms to establish regional manufacturing, R&D, and business centres in the city. Third, to foster domestic innovation and entrepreneurship by supporting startups, SMEs, and mid-size enterprises in the sector. Fourth, to create high-quality employment opportunities and attract global talent by building world-class research, educational, and commercial infrastructure.

Policy analysts project that if implemented effectively, the Central Government's framework could position Hyderabad as Asia's second-largest pharmaceutical and medical device hub within a decade. The city's potential to expand from its current base of Rs 45,000 crore in medical device production to Rs 1,50,000 crore and substantially increase pharmaceutical manufacturing output is considered plausible under the new policy regime. International pharmaceutical enterprises have indicated keen interest in establishing regional operations, contingent upon regulatory clarity and infrastructure readiness—both of which the policy framework directly addresses.

The Central Government's policy initiative represents a pivotal moment for Hyderabad's pharmaceutical and medical device sectors. Industry observers suggest that the next 18-24 months will be critical to implementation success, with the establishment of SEZs, activation of funding mechanisms, and demonstration of regulatory efficiency serving as key milestones. If executed effectively, this initiative could establish Hyderabad as an indispensable node in the global pharmaceutical and medical device supply chain.

V. Krishna The author is a Hyderabad based industrialist